• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

    4.190 -0.160 (-3.68%)
    Streaming Delayed Price Updated: 12:52 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Prelude Therapeutics Incorporated - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
    PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know ↗
     
    Via Benzinga
    News headline image
    The Latest Analyst Ratings for Prelude Therapeutics ↗
     
    Via Benzinga
    News headline image
    Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday ↗
     
    Via Benzinga
    News headline image
    PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024 ↗
    PRLD stock results show that Prelude Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗
    What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
    Via Talk Markets
    News headline image
    Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024 ↗
    PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
    Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
    The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
    Via InvestorPlace
    Topics Artificial Intelligence
    News headline image
    Prelude Therapeutics Announces $25 Million Private Placement
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
    Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
    From Prelude Therapeutics, Inc.; AbCellera
    Via GlobeNewswire
    News headline image
    Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    News headline image
    Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Stocks That Hit 52-Week Lows On Friday ↗
      Friday's session saw 169 companies set new 52-week lows. 
    Via Benzinga
    News headline image
    Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Stocks That Hit 52-Week Lows On Wednesday ↗
      Wednesday's session saw 150 companies set new 52-week lows. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.